Table 1.
Summary of the CCL7 in cardiovascular disease in this review article
| Cardiovascular disease | References | ||
|---|---|---|---|
| Myocardial infarction | CCL7↑ | Risk of death↑/Recurrent myocardial infarction↑/Cardiac inflammation↑ | [29–31] |
| CCL7 (MSCs) ↑ | Cardiac remodeling↑ /Survival of HUVECs ↑/Myocardial inflammation↑ | [32–34] | |
| Cardiac hypertrophy | CCL7↑ | Inflammation (Early phase of cardiac hypertrophy) ↑ | [35, 36] |
| Angiogenesis | CCL7↑ | Formation of blood vessels (Physiological condition) ↑ | [37, 38] |
| Atherosclerosis |
In VSMCs and in carotid artery after balloon angioplasty CCL7↑ CCL7 (monocyte) ↑ |
Arterial thrombosis↑/-altered gut microbial diversity/VSMCs proliferation↑/Lipid accumulation in the aortas↑/ Endothelial expression of ICAM-1, CCL2, CCL7, IL-6, and IL-1β↑ | [39–45] |
| Hypertension | CCL7↑ | 5-year transplant-free survival rates↓/Mononuclear cell and macrophage infiltration↑ | [46–49] |
| Aortic aneurysm | CCL7↑ | M1 phenotype of macrophage (CCR1/JAK2/STAT1) ↑ | [27, 50] |
HUVECs human umbilical vein endothelial cells, ICAM-1 intercellular adhesion molecule-1, IL-1β: interleukin-1β, IL-6: interleukin-6, MSCs mesenchymal stem cells, VSMCs vascular smooth muscle cells